Convection with Conviction to CONVINCE

Online hemodiafiltration (HDF) is an established renal replacement modality for patients with end stage chronic kidney disease that is now gaining clinical acceptance worldwide. Currently, there is a growing body of evidence indicating that treatment with HDF is associated with better outcomes and reduced cardiovascular mortality for dialysis patients. In this presentation current evidence on the effects on clinical outcome is summarized and possible mechanisms of beneficial effect are discussed. Currently, treatment with HDF appears to improve the survival of dialysis patients predominantly due to a reduction in their cardiovascular burden, and this reduction is linked to the sessional convection volume exchanged Information on the effects on patient reported outcome measures is very limited. Presently, large clinical trials are progressing, which hopefully will deliver definite answers in the near future Information on rationale, design and present status will be shared with the audience. 

Press the CLICK HERE or Register button to view.